Observations from the OMERACT Drug Safety Summit, May 2008

Lee S. Simon, C. Vibeke Strand, Maarten Boers, Peter M. Brooks, David Henry, Peter S. Tugwell

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)2110-2113
Number of pages4
JournalJournal of Rheumatology
Issue number9
Publication statusPublished - Sep 2009
Externally publishedYes


Cite this

Simon, L. S., Strand, C. V., Boers, M., Brooks, P. M., Henry, D., & Tugwell, P. S. (2009). Observations from the OMERACT Drug Safety Summit, May 2008. Journal of Rheumatology, 36(9), 2110-2113. https://doi.org/10.3899/jrheum.090590